PWM
ADMA icon

Parkworth Wealth Management’s ADMA Biologics ADMA Stock Holding History

Parkworth Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$328 Buy
18
+13
+260% +$265 ﹤0.01% 762
2025
Q1 		$99 Hold
5
– – ﹤0.01% 941
2024
Q4 		$86 Buy
+5
New +$94 ﹤0.01% 1031

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Parkworth Wealth Management's ADMA Position: Q2 2025 in Review

Parkworth Wealth Management increased its ADMA Biologics (ADMA) stake by 260% in Q2 2025, buying an estimated $265 and bringing the position to 18 shares worth $328. The position accounts for ﹤0.01% of the portfolio, ranked #762.

Parkworth Wealth Management first reported a position in ADMA in Q4 2024 and has held it in 3 quarters since. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Parkworth Wealth Management held 18 shares of ADMA Biologics worth $328 as of Q2 2025.
  • Parkworth Wealth Management bought 13 ADMA Biologics shares in Q2 2025, an estimated $265.
  • ADMA Biologics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #762 holding.
  • Parkworth Wealth Management first reported a position in ADMA Biologics in Q4 2024 and has held it in 3 quarters since.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.